Qtrex Quantum Ltd. · NASDAQ:QTEX

Qtrex Quantum — Inspira Technologies Oxy B.H.N. — Investor Presentation (October 2021)

27 slides from Qtrex Quantum's investor presentation, October 2021

Slide 2: Forward looking-Statements
Forward looking-Statements This presentation of InspiraTM Technologies Oxy B.H.N. Ltd. (the “Company”) contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities law. Words such as “expects,” “intends,” “plans,” “believes,” “seeks,”
Slide 3: Mechanical Ventilation Has Significant Downsides
Mechanical Ventilation Has Significant Downsides¹ˉ³ MV requires intrusive intubation, coma induction, and can be very traumatic for patients: Potential Risks & Complications High Cost of Treatment • Ventilator-induced lung injury (VILI) • Long hospital stays • Ventilator-associated pneumonia (VAP) •
Slide 4: Inspira developing early extracorporeal blood oxygenation system
InspiraTM Technologies is developing a potentially minimally invasive, cost-effective early extracorporeal blood oxygenation system that utilizes a proprietary hemo-protective Flow technology to rebalance oxygen saturation levels in one minute*, while the patient is awake and maintaining spontaneous
Slide 6: Investment Highlights
Investment Highlights A novel therapy Approaching both ICU and non-ICU Revolutionary early extracorporeal markets respiratory support system,intended Cost-effective, designed for to rebalance saturation and carbon deployment in and outside the ICU, in dioxide levels in patients with acute urban and
Slide 7: Our mission is to become the new standard of care
Our mission is to become the new standard of care, for acute respiratory patients, to be applied in awake and breathing patients. Copyright © 2018-2021 Inspira Technologies OXY B.H.N. LTD., All rights reserved 7
Slide 8: The ART™ device
The ART™ device Early Extracorporeal Respiratory Support The product is currently in a developmental stage and has not yet been tested or used in humans and hasCopyright not been approved © 2018-2021 by the Inspira U.S. Food Technologies OXY and B.H.N.Drug Administration LTD., All rights reserved (F
Slide 9: The ART Device
THE ARTTM DEVICE Taking the load off the lungs INSERT WITHDRAW ENRICH CIRCULATE REBALANCE Dual lumen cannula Utilizing hemo-protective Blood is enriched with The enriched blood is The returned enriched inserted into the flow technology, the blood high concentrations of returned to the body blood reb
Slide 10: The ART
THE ARTTM The ART device is comprised of a permanent module and a disposable respiratory support Oxygenator unit. The company’s strategic business model is designed to enable the Initiation System extension of acute respiratory care beyond the ICU. Pump Copyright © 2018-2021 Inspira Technologies OXY
Slide 11: ART Device Primary Components
ARTTM Device Primary Components Dual Lumen Cannula & Hemo-Protective Initiation System Disposable Respiratory Adjustable Dual Lumen Flow Pump Support Unit Component: Component: Component: Component: Low impact radiography-free dual Proprietary hemo-protective Autonomous initiation Plug-and-play disp
Slide 12: ART's Innovative Features
ART’s Innovative Features Hemo-protective flow technology aimed to reduce the risks of hemolysis & thrombosis Single insertion point of dual-lumen cannula aimed at lowering the risk of multiple infections & bleeding Eliminates Proprietary plug-and-play disposable unit expected to reduce need for ICU
Slide 13: ART's Proprietary Hemo-Protective Flow Technology Features
ART’s Proprietary Hemo-Protective Flow Technology Features Presenting innovative features expected to minimize hemolysis & thrombosis Hemolysis Thrombosis ART’s features reduction reduction Disposable set designed for Low flow – V V high velocity A low-volume oxygenator V Pump head design for low fl
Slide 14: ART's Respiratory Support System Potential Benefits
ART's Respiratory Support System Potential Benefits The patient's perspective The clinician's perspective The hospital perspective • Immediate oxygen saturation elevation • Clinicians would be able to offer an • Reduced costs associated with MV • Decreased work of breathing: alternative to mechanica
Slide 15: ART Offers Two Intervention Modalities
ARTTM Offers Two Intervention Modalities EARLY INTERVENTION ADJUNCTIVE THERAPY, SUPPORTING THE USE OF MV WHO Avoid VALI, Awake & breathing Ventilated patients patients with deteriorating under induced coma respiratory failure WHAT VALUE • Reduce risk of ventilator induced • Avoid intubation, coma an
Slide 16: Study Results
Study Results Substantial ongoing positive changes in the blood oxygenation levels Oxygen Saturation levels Partial Pressure of Oxygen Partial Pressure of carbon dioxide 94.76% 32.13 mmHg 26.91 mmHg 49.3 mmHg 65.08 mmHg 84.96% No significant change SaOշSAO2 (P=0.0001) (P<0.0001) PaOշ (P<0.0001) PAO2
Slide 17: Intended Patient Population and Lines of Therapy
Intended Patient Population and Lines of Therapy Patient Population Acute hypoxemic failure Adult COPD patients (Chronic adult patients Obstructive Pulmonary Disease) Non-Invasive Ventilation¹ RESPIRATORY DETERIORATIO • Nasal mask • HFNC (High • Face mask Flow Nasal • Nasal plugs Cannula) • BiPAP •
Slide 18: $20Bn Total Addressable Market for the ART
$20Bn Total Addressable Market for the ARTTM $20 Bn Total Market* 20 million globally 1,250$ per per year¹ treatment/disposable unit (estimated target price) *80% of 20 million¹ patients annually¹(treated today by MV) at a direct treatment cost of $1,250 for ART disposables unit (cost per patient pe
Slide 19: Market Penetration and Gaining Market Share
Market Penetration and Gaining Market Share We have developed a flexible business model to drive global deployment Multiple Healthcare Centers, PRICING MODEL consumer types Medical Services & Medical Device Companies ART device distributed as an OPEX when bundled with 15 disposable respiratory suppo
Slide 20: Reimbursement Strategy
Reimbursement Strategy Inspira plans to utilize existing CPT Codes using a “New Approach” to an existing procedure Expected to eliminate Aimed to reduce length of complications stay & re-admissions associated with MV Designed to reduced Designed to reduce costs & operational hospital & staff burden
Slide 21: Go-to-Market Strategy
Go-to-Market Strategy Establishing multiple recurring revenue streams across medical sectors & markets PURSUING WORLD-WIDE COLLABORATING WITH STRATEGIC OPTIONAL TREATMENT REGULATORY APPROVALS MEDICAL CENTERS & INDICATIONS PROFESSIONAL ASSOCIATIONS United States Strategic partners for regional • Earl
Slide 22: Regulatory Submission (Multi-Step approach)
Regulatory Submission (Multi-Step approach) Components ART ARTTM 510(k) Support De Novo* ECLS 510(k) Q4-2021 Q4-2022 Q3-2023 To-date the ART500 has not been tested on humans and is subject to the regulator’s requirement. *Will require a new 510(k) marketing clearance or, depending on the modificatio
Slide 23: Targeting Major Milestones 2021-2023
Regulatory Filings Distribution Agreement Targeting Major Milestones 2021-2023 Strategic Agreement Product Deployment/Pre-Sales Medical Collaboration Clinical evidence/clinical trial H1-2022 H1-2023 Strategic Agreement ART support ECLS Deployment COMPONENT in Leading Hospital Distribution Agreement
Slide 24: Leadership
Leadership Prof. Benad Goldwasser, MD, MBA Joe Hayon, MBA Dagi Ben-Noon, BSc Dr. Udi Nossinovitch, MD, PhD Chairman Co-Founder, President & CFO Co-Founder, CEO Co-Founder, CSO Urologic surgeon, inventor, Former CFO, CIO and Corporate Co-Founded Nano Dimension Cardiologist, ICU Physician & entreprene
Slide 25: Scientific Advisory Board
Scientific Advisory Board Prof Eli Gabbay, MD, FRACP Dr. Yigal Kasif, MD Dr. Avraham Abutbul, MD Dr. Orit Cohen Jacob, MDV Respiratory Advisor ECMO Advisor ICU Respiratory Advisor Clinical & Research Advisor Respiratory physician & specialist in Cardiac Surgeon & Director of Senior physician at the
Slide 26: Scientific Advisory Board - cont.
Scientific Advisory Board - cont. Dr. Dekel Stavi, MD Dr. Yael Lichter, MD Intensivist Advisor Intensivist Advisor Has considerable experience in leadership A director of the Medical ICU at and Extracorporeal Life Support programs, Sourasky Medical Center since 2020 cardiology aspects of Intensive C

Inspira Technologies Oxy B.H.N. — Investor Presentation (October 2021) on 6ix

Qtrex Quantum — Inspira Technologies Oxy B.H.N. — Investor Presentation (October 2021)

Slide 1: Revolutionizing Acute Respiratory Care

Slide 2: Forward looking-Statements

Slide 3: Mechanical Ventilation Has Significant Downsides

Slide 4: Inspira developing early extracorporeal blood oxygenation system

Slide 5: Vision

Slide 6: Investment Highlights

Slide 7: Our mission is to become the new standard of care

Slide 8: The ART™ device

Slide 9: The ART Device

Slide 10: The ART

Slide 11: ART Device Primary Components

Slide 12: ART's Innovative Features

Slide 13: ART's Proprietary Hemo-Protective Flow Technology Features

Slide 14: ART's Respiratory Support System Potential Benefits

Slide 15: ART Offers Two Intervention Modalities

Slide 16: Study Results

Slide 17: Intended Patient Population and Lines of Therapy

Slide 18: $20Bn Total Addressable Market for the ART

Slide 19: Market Penetration and Gaining Market Share

Slide 20: Reimbursement Strategy

Slide 21: Go-to-Market Strategy

Slide 22: Regulatory Submission (Multi-Step approach)

Slide 23: Targeting Major Milestones 2021-2023

Slide 24: Leadership

Slide 25: Scientific Advisory Board

Slide 26: Scientific Advisory Board - cont.

Slide 27: THANK YOU